Projects funded by the NCN

Information on the principal investigator and host institution

Information of the project and the call

Keywords

Equipment

Delete all

Influence of AKT signaling pathway on CD20 expression and antitumor activity of therapeutic monoclonal antibodies.

2013/11/B/NZ5/03240

Keywords:

B lymphocytes CD20 antigen transcriptional regulation AKT PI3K TLR dendritic cells

Descriptors:

  • NZ6_2: Clinical immunology
  • NZ6_8: Other related subjects
  • NZ5_7: Human disease treatment

Panel:

NZ5 - Human and animal noninfectious diseases: etiology, mechanisms, diagnosis and treatment of diseases, poisonings and injuries (without neurological diseases)

Host institution :

Warszawski Uniwersytet Medyczny, I Wydział Lekarski

woj. mazowieckie

Other projects carried out by the institution 

Principal investigator (from the host institution):

dr Beata Pyrzyńska 

Number of co-investigators in the project: 6

Call: OPUS 6 - announced on 2013-09-16

Amount awarded: 1 074 759 PLN

Project start date (Y-m-d): 2014-08-08

Project end date (Y-m-d): 2017-08-07

Project duration:: 36 months (the same as in the proposal)

Project status: Project settled

Equipment purchased [PL]

  1. Dewar do ciekłego azotu (do przechowywania kriotubek).
  2. Oprogramowanie do komputera (2 szt.) (4 000 PLN)
  3. Zamrażarka niskotemperaturowa (-86C) (68 000 PLN)
  4. Odyssey Fc (system do techniki Western blot) (185 000 PLN)
  5. Zestaw do transferu białek (do techniki Western blotting).

Information in the final report

  • Publication in academic press/journals (2)
  • Articles in post-conference publications (10)
  1. HDAC6 inhibition up-regulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies.
    Authors:
    Bobrowicz M., Dwojak M., Pyrzynska B., Stachura J., Muchowicz A., Berthel E., Dalla Venezia N., Kozikowski M., Siernicka M., Miazek N., Zapala P., Domagala A., Bojarczuk K., Malenda A., Barankiewicz J., Graczyk-Jarzynka A., Zagozdzon A., Gabrysiak M., Diaz J.J., Karp M., Lech-Maranda E., Firczuk M., Giannopoulos K., Efremov D.G., Laurenti L., Baatout D., Frenzel L., Malinowska A., Slabicki M., Zenz T., Zerrouqi A., Golab J., Winiarska M.
    Academic press:
    Blood (rok: 2017, tom: 130(14), strony: 1628-1638), Wydawca: American Society of Hematology
    Status:
    Published
    DOI:
    10.1182/blood-2016-08-736066 - link to the publication
  2. FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy.
    Authors:
    Pyrzynska B., Dwojak M. , Zerrouqi A. , Morlino G., Zapala P., Miazek N., Zagozdzon A., Bojarczuk K., Bobrowicz M., Siernicka M., Machnicki M.M., Gobessi S., Barankiewicz J., Lech-Maranda E., Efremov D.G., Juszczynski P., Calado D., Golab J., Winiarska M.
    Academic press:
    OncoImmunology (rok: 2018, tom: 7(5), strony: e1423183 (9 stron)), Wydawca: Taylor & Francis Group
    Status:
    Published
    DOI:
    10.1080/2162402X.2017.1423183 - link to the publication
  1. Improved response of B-cell malignancies to rituximab upon FOXO1 inhibition.
    Authors:
    Pyrzynska B., Zerrouqi A., Dwojak M., Morlino G., Zapala P., Miazek N., Zagozdzon A., Calado D., Golab J., Winiarska M.
    Conference:
    EACR-AACR-SIC Special Conference 2017: The Challenges of Optimizing Immuno- and Targeted Therapies. (rok: 2017, ), Wydawca: European Association for Cancer Research (EACR), American Association for Cancer Research (AACR), Italian Cancer Society (SIC)
    Data:
    konferencja 24-27 czerwca
    Status:
    Published
  2. Mechanism of lymphoma resistance to anti-CD20 immunotherapy mediated by FOXO1.
    Authors:
    Pyrzynska B., Zerrouqi A., Dwojak M., Miazek N., Zapala P., Zagozdzon A., Bojarczuk K., Bobrowicz M., Siernicka M., Golab J., Winiarska M.
    Conference:
    EMBO Workshop: "To-B or not to-B: B-cells in health and disease" (rok: 2017, ), Wydawca: European Molecular Biology Organization (EMBO)
    Data:
    konferencja 10-14 września
    Status:
    Published
  3. PTEN regulates the CD20 antigen expression and affects rituximab-based therapy of lymphoma malignancies.
    Authors:
    Pyrzynska B, Bojarczuk K, Siernicka M, Dwojak M, Bobrowicz M, Miazek N, Zapala P, Zagozdzon A., Bil J, Golab J, Winiarska M.
    Conference:
    AACR Annual Meeting (rok: 2015, ), Wydawca: American Association for Cancer Research (AACR)
    Data:
    konferencja 18-22 kwietnia
    Status:
    Published
  4. FOXO1 controls CD20 expression and influences B-cell lymphoma response to rituximab-based immunotherapy.
    Authors:
    Dwojak M., Pyrzynska B., Zerrouqi A., Morlino G., Zapala P., Miazek N., Bojarczuk K., Bobrowicz M., Machnicki M., Golab J., Calado D., Winiarska M.
    Conference:
    Congress of the European Hematology Association (EHA) (rok: 2017, ), Wydawca: European Hematology Association (EHA)
    Data:
    konferencja 22-25 czerwca
    Status:
    Published
    DOI:
    link to the publication
  5. FOXO1 is transcriptional regulator of malignant B-cell surface antigen CD20, the target for therapeutic monoclonal antibodies.
    Authors:
    Pyrzynska B., Zerrouqi A., Dwojak M., Morlino G., Zapala P., Miazek N., Zagozdzon A., Bojarczuk K., Bobrowicz M., Siernicka M., Machnicki M.M., Barankiewicz J., Lech-Maranda E., Juszczynski P., Calado D., Golab J., Winiarska M.
    Conference:
    AACR Special Conference on "Tumor Immunology and Immunotherapy" (rok: 2017, ), Wydawca: American Association for Cancer Research (AACR)
    Data:
    konferencja 1-4 października
    Status:
    Published
    DOI:
    link to the publication
  6. Regulation of CD20 expression by AKT-Forkhead signaling cascade influences the efficacy of immunotherapy with monoclonal antibodies.
    Authors:
    Pyrzynska B., Dwojak M., Zagozdzon A., Miazek N., Zapala P., Bojarczuk K., Bobrowicz M., Golab J., Zerrouqi A., Winiarska M.
    Conference:
    International Conference on Human and Translational Immunology (rok: 2016, ), Wydawca: Aegean Conferences, www.aegeanconferences.org
    Data:
    konferencja 16-21 września
    Status:
    Published
  7. FOXO1 determines Non-Hodgkin lymphomas reponse to anti-CD20-based therapy.
    Authors:
    Zerrouqi A., Pyrzynska B., Dwojak M., Morlino G., Zapala P., Miazek N., Golab J., Winiarska M.
    Conference:
    AACR Special Conference on "Advances in modeling cancer in mice: technology, biology, and beyond" (rok: 2017, ), Wydawca: American Association for Cancer Research (AACR)
    Data:
    konferencja 24-27 września
    Status:
    Published
    DOI:
    link to the publication
  8. B-cell lymphoma response to anti-CD20 antibodies based therapies is tightly modulated by FOXO1 mediated MS4A1 gene transcription.
    Authors:
    Zerrouqi A., Pyrzynska B., Dwojak M., Miazek N., Zapala P., Golab J., Winiarska M.
    Conference:
    AACR Special Conference on "Tumor Immunology and Immunotherapy" (rok: 2017, ), Wydawca: American Association for Cancer Research (AACR)
    Data:
    konferencja 1-4 października
    Status:
    Published
    DOI:
    link to the publication
  9. FOXO1 promotes resistance of Non-Hodgkin lymphomas to anti-CD20-based therapy.
    Authors:
    Zerrouqi A., Pyrzynska B., Dwojak M., Zapala P., Miazek N., Machnicki M.M., Golab J., Winiarska M.
    Conference:
    EACR-AACR-SIC Special Conference 2017: The Challenges of Optimizing Immuno- and Targeted Therapies. (rok: 2017, ), Wydawca: European Association for Cancer Research (EACR), American Association for Cancer Research (AACR), Italian Cancer Society (SIC)
    Data:
    konferencja 24-27 czerwca
    Status:
    Published
  10. HDAC6 inhibition increases CD20 level by stimulating translation of CD20 mRNA.
    Authors:
    Graczyk-Jarzynka A., Bobrowicz M., Dwojak M., Stachura J., Berthel E., Pyrzynska B., Siernicka M., Miazek N., Zapala P., Dalla-Venezia N., Golab J., Winiarska M.
    Conference:
    Congress of the European Hematology Association (EHA) (rok: 2017, ), Wydawca: European Hematology Association (EHA)
    Data:
    konferencja 22-25 czerwca
    Status:
    Published
    DOI:
    link to the publication

O Narodowym Centrum Nauki

Finansowanie nauki

Współpraca zagraniczna

Centrum prasowe

Deklaracja dostępności
Przetwarzanie danych osobowych
Polityka cookies

Partnerzy